#ES­MO18: Crowned with a break­through ti­tle, Clo­vis takes an ear­ly lead as it races for a fast OK for Rubra­ca in prostate can­cer

MU­NICH — With Lyn­parza from As­traZeneca and Mer­ck ex­pand­ing on a big lead for ovar­i­an and breast can­cer, Clo­vis On­col­o­gy $CLVS is map­ping a sep­a­rate route in prostate can­cer for their PARP ri­val Rubra­ca that may pay off hand­some­ly.

The Boul­der, CO-based biotech turned up in Mu­nich to­day to un­veil an ear­ly look at Phase II da­ta from their TRI­TON2 study, with a 44% con­firmed ob­jec­tive re­sponse rate in 25 sec­ond-line, RE­CIST-evalu­able pa­tients with a BR­CA1/2 al­ter­ation. Re­searchers al­so claimed a 51% PSA re­sponse rate in 45 prostate can­cer pa­tients as well as some bio­mark­er re­ac­tions that they count as a promis­ing sign for the fu­ture da­ta to come out of the pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA